Journal
WORLD JOURNAL OF CLINICAL ONCOLOGY
Volume 13, Issue 3, Pages 219-236Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.5306/wjco.v13.i3.219
Keywords
Triple-negative breast cancer; Early disease; Immunotherapy; Biomarkers; Metastatic disease
Categories
Ask authors/readers for more resources
Triple-negative breast cancer is a complex and heterogeneous disease with historically limited treatment options. Immunotherapy has emerged as an important alternative treatment, showing impact on progression-free survival and overall survival in selected populations. Further research is needed to explore potential predictive biomarkers of response to treatment in this subtype of breast cancer.
Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in the management of this malignancy, showing an impact on progression-free survival and overall survival in selected populations. In this review we focused on immunotherapy and its current relevance in the management of TNBC, including various scenarios (metastatic and early -neoadjuvant, adjuvant-), new advances in this subtype and the research of potential predictive biomarkers of response to treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available